Transcode Therapeutics Inc (RNAZ) — Tangible Net Worth Ratio
Transcode Therapeutics Inc (RNAZ) has a Tangible Net Worth Ratio of 20.9% as of March 2026. This metric is calculated by deducting intangible assets ($114.30 Million) from net assets ($144.52 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. For live market cap and overall valuation, see market value of Transcode Therapeutics Inc.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Transcode Therapeutics Inc Tangible Net Worth Ratio (2021–2025)
This chart shows how Transcode Therapeutics Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 20.9%, reflecting net assets of $144.52 Million with intangible assets of $114.30 Million USD. Also explore Transcode Therapeutics Inc (RNAZ) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Transcode Therapeutics Inc (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Transcode Therapeutics Inc from 2021 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See Transcode Therapeutics Inc (RNAZ) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -1005.9% | $10.34 Million | $114.30 Million | $162.40 Million | ▼ -1105.9 pp |
| 2023 | 100.0% | $1.64 Million | $0.00 | $5.17 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $3.24 Million | $0.00 | $7.59 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $20.40 Million | $0.00 | $22.94 Million | — |